Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Tech for Efficiency: Applications and Apparatuses to Accomplish More - 2Uncover the Manageable Fish Practices: Sea agreeable Feasting
- 3Figure out How to Recognize Early Indications of Depressions
- 4Two policemen injured at religious youth protest in Jerusalem marking Ahuvia Sandak's death
- 5Are your hormones imbalanced? Doctors explain how to know if you need testing
- Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
- Viable Tips for Seniors to Purchase a Minimal expense Jeep Wrangler
- Amateur's Manual for Venture Strategies for Tenderfoots
- Find the Advantages of Innovative Leisure activities: Supporting Creative mind and Self-Articulation
- The Best Games On the planet
- Best Getaway destination: Ocean side, Mountain, or City
- The Most Compelling Innovation Developments Somewhat recently
- Moldova says Russian drones violated airspace
- Figure out How to Track the Establishment of New 5G Pinnacles
